Projected disease burden and treatment eligibility of patients with diffuse large B-cell and mantle cell lymphoma in the United States over the next decade
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2026.101291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Dan Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, NJ, 07065, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Cost of Illness. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Georgia Department of Public Health, Centers for Disease Control and Prevention, Merck Sharp and Dohme United Kingdom.
Abstract (Originalsprache)
INTRODUCTION: There is lack of comprehensive and up-to-date forecasted estimates for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), with inconsistencies in existing literature. The study estimated and forecasted incidence, prevalence, and treatment-eligible patient counts by line of therapy (LoT) for DLBCL and MCL in the US from 2023 to 2032. METHODS: Historical incidence rates for 2017-2022 (excluding 2020) from SEER-21 were used for projections. A validated joinpoint regression model forecasted age- and gender-specific incidence rates. A validated prevalence model incorporating incidence, survival, and cure likelihood estimated 5-, 10-, 15-, and 20-year prevalences. A new model estimated treatment-eligible DLBCL and MCL patients counts by LoT, integrating projected incidence, literature estimates on re‑entry patients, and SEER-Medicare treatment‑pattern data. RESULTS: From 2023 to 2032, DLBCL incidence is projected to rise by 7% (28,838 to 30,772) and MCL by 6% (3,377 to 3,589). The 5-, 10-, 15-, and 20-year prevalences are expected to increase by 11%, 16%, 18%, and 20% for DLBCL, and by 8%, 13%, 16%, and 19% for MCL. In DLBCL, treatment-eligible patients are estimated to increase by 7% in 1L (33,120 to 35,523) and by 8% in later lines (2L: 9,243 to 9,976; 3L: 4,466 to 4,821; 4L: 2,163 to 2,335). In MCL, treatment-eligible patients are expected to increase by 6% across all LoT (1L: 3,376 to 3,591; 2L: 1,220 to 1,297; 3L: 685 to 729; 4L: 379 to 405). CONCLUSION: Projections indicate growing burdens of DLBCL and MCL in the US, informing healthcare planning and resource allocation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, NJ, 07065, USA.
- Merck & Co., Inc., Rahway, NJ, 07065, USA. Electronic address: helmneh.sineshaw@merck.com.
Förderung
- Georgia Department of Public Health
- Centers for Disease Control and Prevention
- Merck Sharp and Dohme United Kingdom
- University of Southern California
- National Cancer Institute
Zitieren
APA
Lin, D., Shao, C., Ma, J., Burcu, M., & Sineshaw, H. M. (2026). Projected disease burden and treatment eligibility of patients with diffuse large B-cell and mantle cell lymphoma in the United States over the next decade. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101291
Vancouver
Lin D, Shao C, Ma J, Burcu M, Sineshaw HM. Projected disease burden and treatment eligibility of patients with diffuse large B-cell and mantle cell lymphoma in the United States over the next decade. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101291
BibTeX
@article{Lin2026,
author = {Lin, Dan and Shao, Changxia and Ma, Jiemin and Burcu, Mehmet and Sineshaw, Helmneh M},
title = {Projected disease burden and treatment eligibility of patients with diffuse large B-cell and mantle cell lymphoma in the United States over the next decade},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2026.101291}
}
EUVIMED